SC 13G/A: Viridian Therapeutics, Inc.\DE
Ticker: VRDN · Form: SC 13G/A · Filed: Feb 14, 2024 · CIK: 1590750
Sentiment: neutral
Topics: sc-13g-a
AI Summary
SC 13G/A filing by Viridian Therapeutics, Inc.\DE.
Risk Assessment
Risk Level: low
Filing Stats: 1,524 words · 6 min read · ~5 pages · Grade level 7.2 · Accepted 2024-02-14 16:08:06
Key Financial Figures
- $0.01 — Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class o
Filing Documents
- tm245955d6_sc13ga.htm (SC 13G/A) — 57KB
- 0001104659-24-023624.txt ( ) — 59KB
If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b)
Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); Page 6 of 9 Pages (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________________________
Ownership
Item 4. Ownership. See Items 5-9 and 11 on the cover page for each Reporting Person, and Item 2, which information is given as of the Event Date of this Schedule 13G/A1, and which consists of: (x) 4,022,866 shares of Common Stock owned by the Fund; (y) 771,622 shares of Common Stock owned by the Account; and (z) 509,825 shares of Common Stock underlying preferred stock that can be converted within 60 days. The percentages of beneficial ownership contained herein are based on: (x) 52,586,039 shares of Common Stock outstanding as of November 7, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on November 13, 2023; plus (y) 509,825 shares of Common Stock underlying the preferred stock referred to above.
Ownership of Five Percent or Less of a Class
Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:
Ownership of More than Five Percent on Behalf of Another
Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable.
Identification and Classification of the Subsidiary Which
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not applicable.
Identification and Classification of Members of the Group
Item 8. Identification and Classification of Members of the Group. Not applicable.
Notice of Dissolution of Group
Item 9. Notice of Dissolution of Group. Not applicable. Page 7 of 9 Pages
Certification
Item 10. Certification. (a) Not applicable. (b) Not applicable. (c) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11. Page 8 of 9 Pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 14, 2024 Paradigm BioCapital Advisors LP Paradigm BioCapital Advisors GP LLC Paradigm BioCapital International Fund Ltd. By: /s/ David K. Kim Name: David K. Kim Title: Authorized Signatory /s/ Senai Asefaw, M.D. Senai Asefaw, M.D. Page 9 of 9 Pages